Stock NBIX NEUROCRINE BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-17 pm EDT 		5-day change 1st Jan Change
133.2 USD +0.18% Intraday chart for Neurocrine Biosciences, Inc. -3.52% +1.12%
Apr. 17 Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test MT
Apr. 16 Neurocrine Biosciences, Sentia Medical Sciences Extend Partnership on Prospective Drug Development MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test
MT
Neurocrine Biosciences, Sentia Medical Sciences Extend Partnership on Prospective Drug Development
MT
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
AQ
Sentia Medical Sciences Inc. and Neurocrine Biosciences, Inc. Extend Research Collaboration to Discover Novel CRF Peptides
CI
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results
PR
Morgan Stanley Lifts Price Target on Neurocrine Biosciences to $160 From $150, Sees Upside to Shares Ahead of Mid-Stage Readouts; Overweight Kept
MT
Neurocrine Biosciences Doses First Patient in Phase 2 Depressive Disorder Study
MT
Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
PR
Neurocrine Biosciences, Inc. Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
CI
Neurocrine Biosciences Starts Phase 1 Trial of Investigational Neuropsychiatric Drug
MT
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
PR
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
CI
JPMorgan Adjusts Price Target on Neurocrine Biosciences to $158 From $148, Maintains Overweight Rating
MT
Transcript : Neurocrine Biosciences, Inc. Presents at Stifel Virtual 2024 CNS Day, Mar-19-2024 02:00 PM
Transcript : Neurocrine Biosciences, Inc. Presents at UBS Virtual CNS Day 2024, Mar-18-2024 12:00 PM
Neurocrine Biosciences Insider Sold Shares Worth $5,576,710, According to a Recent SEC Filing
MT
Neurocrine Biosciences Insider Sold Shares Worth $420,419, According to a Recent SEC Filing
MT
Transcript : Neurocrine Biosciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 10:15 AM
Oppenheimer Adjusts Neurocrine Biosciences Price Target to $200 From $170, Maintains Outperform Rating
MT
Transcript : Neurocrine Biosciences, Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-12-2024 08:40 AM
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NBIX Stock
  4. News Neurocrine Biosciences, Inc.